Introduction
Human IgA is abundant in the seromucous secretions which bathe mucosal surfaces, such as those lining the lungs, gut, and genitourinary tracts. These surfaces represent major potential sites of invasion and the immune protection offered by secretory IgA, as the predominant antibody at these sites, serves as a critical 'first line of defence' against many bacteria and viruses (1) . Moreover, evidence is accumulating that IgA present in serum plays an important role in a 'second line of defence' against microorganisms that have penetrated the mucosal barrier (2, 3) .
IgA performs the dual role of all antibodies, of both recognising foreign invaders and triggering their elimination. For IgA, this latter effector function involves the interaction of its 4 not identical, making comparisons of interest (18, 19) . Importantly, these IgA-BPs bind human IgA of both subclasses and bind both serum IgA and secretory IgA (15, 20) .
In GBS, binding of IgA is due to the β protein, which is unrelated to the IgA-BPs of S. pyogenes (21, 22) and has a 73-residue IgA-binding region that does not vary in sequence between strains (23) . The β protein binds human serum IgA of both subclasses and has the remarkable property that it binds poorly to secretory IgA, the molecular form of IgA that predominates on mucous membranes (24) .
Here, we report experiments aimed at analysing the interaction between IgA-Fc and 
Experimental Procedures

Bacterial strains
The S. pyogenes strain AL168 expresses the Sir22 protein (15) . Strain AL168mrp22 -sir22 -is a derivative of AL168 lacking expression of the two M proteins Mrp22 and Sir22 (26) . The M-negative S. pyogenes strain JRS145 and its derivative JRS145/pJRS264, which expresses the Arp4 protein, have been described (27) . The GBS strain A909, which expresses the β protein (11), was obtained from Dr J. Michel (Channing Laboratory, Boston, Mass.). A β-negative derivative of A909 was constructed by replacement of the β gene with a kanamycin resistance cassette 2 . Streptococcal strains were grown in Todd-Hewitt broth (Oxoid, Basingstoke, Hampshire, U.K.) at 37 0 C, without shaking.
Purified bacterial proteins and peptides
The S. pyogenes proteins Arp4 and Sir22 were purified after expression in E. coli (15) . Two deletion derivatives of Arp4 with non-overlapping deletions in the IgA-binding region, the Arp4∆450 and Arp4∆451 proteins, were constructed and purified as described (18, 28) . The group B streptococcal β and Rib proteins were purified from streptococcal extracts (29) .
Protein G was purchased from Calbiochem-Novagen Sciences (Nottingham, U.K). A synthetic 50-residue IgA-binding peptide, derived from the Sir22 protein, has been described (25) . This peptide contains a C-terminal C residue, not present in Sir22, that promotes dimerization and thereby enhances IgA-binding (30) . A 53-residue synthetic peptide (M5-N), derived from the N-terminal region of the non-IgA-binding streptococcal M5 protein, was purchased from the Department of Clinical Chemistry, Malmö General Hospital, Sweden.
This peptide includes 50 residues derived from the M5 protein and also includes the sequence YYC added at the C-terminal end, allowing radiolabelling at the tyrosine residues and dimerisation via the cysteine residue.
Analysis of purified bacterial proteins by Western blot was performed as described (29) , using rabbit anti-Sir22 serum and mouse anti-β serum for analysis of cross-reactivity.
The blotting membranes were incubated with antiserum diluted 1000-fold, followed by 6 incubation with radiolabelled protein G (for rabbit IgG) or protein A (for mouse IgG) and autoradiography. Control membranes were incubated with preimmune serum.
Human IgG/IgA domain swap and mutant IgA1 antibodies
All the recombinant anti-NIP antibodies used were chimeric (heavy chains comprised human constant domains and murine variable domain, light chains (λ) were murine). They included previously described wildtype human IgA1 and IgG1 (7, 31) , and the IgG1/IgA1 domain swap antibodies α1α2γ3 and γ1γ2α3 (7). IgA1 mutants with single or double residue substitutions in the two interdomain loops (L257R, G259R, P440R, P440A, A442R, F443R
and LA441-442MN) [numbering according to the commonly adopted scheme used for IgA1
Bur (32)] have also been described (7) . Recombinant antibodies were purified from supernatants of CHO-K1 transfectants by affinity chromatography on NIP-Sepharose (7). 
Analysis of Ig binding by ELISA
Binding assays with whole bacteria
Washed suspensions of bacteria (~5 x 10 9 /ml) were prepared as described (26) with PBSAT, the radioactivity associated with the pelleted bacteria was determined in a γ-counter. All incubations were performed at room temperature. Binding is expressed as a percentage of the radioactivity added to each tube. Binding to control bacteria (≤1%) has been subtracted. All determinations were made in duplicate.
Binding to Sir22 on the bacterial cell surface was analyzed with S. pyogenes strain AL168, using the non-IgA-binding mutant AL168mrp22 -sir22 -as a negative control. Binding to Arp4 on the surface of S. pyogenes was performed with strain JRS145/pJRS264, with JRS145 as the negative control, and binding to β on the surface of GBS was analyzed with strain A909, using a β-negative mutant of this strain as the negative control.
Inhibition of rosetting
Human erythrocytes were derivatized with NIP and sensitized with wildtype IgA1 at 200 µg/ml as described (7) . Neutrophils were isolated as described (7) and resuspended in PBS containing 0.1% (w/v) BSA (PBS/BSA). In the inhibition assay, which was essentially a modification of a previously described method (33) , diluted coated erythrocytes and inhibitor protein (peptide, bacterial proteins, or their control peptide or proteins), both in PBS/BSA, were incubated at room temperature for 1 hour (except for β protein and protein G where overnight incubation was used) in wells of a V-bottomed microtiter plate. Neutrophils (∼50,000) in PBS/BSA were added and mixed carefully, the plates incubated for 10 min, The results were normalised so that the mean rosetting level seen in the absence of inhibitor gave 0% normalised rosette inhibition. For each inhibitor, experiments were performed at least twice, each time using neutrophils from a different donor.
Inhibition of neutrophil respiratory burst
The inhibition assay was essentially a modification of a previously described chemiluminescence assay of respiratory bursts (7 
Results
Immunochemical comparison of streptococcal IgA-binding proteins
The ∼40 kDa Arp4 and Sir22 proteins from S. pyogenes are both members of the M protein family and share structural similarities, including a high degree of residue identity in the 29-residue IgA-binding region ( Figure 1 ). As expected, antibodies to Sir22 were found to crossreact with Arp4 ( Figure 1 ). However, the ∼125 kDa β protein of GBS lacks residue identity with Arp4 and Sir22 and did not react with anti-Sir22 antibody, nor did anti-β antibodies 9 recognise Arp4 or Sir22. These data confirm that the IgA-BPs of S. pyogenes and GBS are unrelated, underlining the interest in comparing their functional properties.
Contribution of IgA-Fc domains to interaction with IgA-binding proteins
To analyse the contribution of the Cα2 and Cα3 domains of IgA-Fc to the binding of streptococcal IgA-BPs, we used two domain swap antibodies in which homologous domains are exchanged between IgA1 and IgG1. These domain swaps are designated γ1γ2α3 (constant domain structure Cγ1, Cγ2, Cα3), and α1α2γ3 (constant domain structure Cα1, Cα2, Cγ3) ( Table I ). The ability of the constructs to bind the three streptococcal IgA-BPs, and the IgAbinding peptide derived from Sir22, was analysed by ELISA ( Figure 2 ).
Because intact Sir22 binds both IgA and IgG (15), the IgA/IgG domain swap antibodies could not be used to provide information on the IgA binding requirements of Sir22.
However, the Sir22-derived peptide, Arp4 and β protein did not bind wildtype IgG1 in the ELISA, so this approach was useful to illustrate the relative contributions of the two IgA-Fc domains to the interaction site. For all these three IgA-binding molecules, we observed that the γ1γ2α3 antibody bound with an apparent affinity generally comparable to wildtype IgA1
( Figure 2 ). In contrast, no binding was observed for the α1α2γ3 antibody. Several streptococcal proteins/peptides that do not bind IgA were used as controls, and all were unable to bind to either wildtype IgA1 or the swap antibodies. Together, these results suggest that the Cα3 domain makes a major contribution to the binding site for these IgAbinding molecules.
To analyse whether the findings using purified bacterial IgA-binding proteins give a true reflection of the reactivity of the proteins when expressed on the bacterial cell surface,
we performed binding studies with whole bacteria. Due to the IgG-binding ability of the S.
pyogenes strains expressing Sir22 and Arp4 (34), we were unable to analyse whole S.
pyogenes bacteria for ability to bind the IgA/IgG domain swap antibodies, but could perform studies with whole GBS bacteria expressing the β protein ( Figure 3 ). Neither IgG1 nor the domain swap α1α2γ3 bound to the β-expressing GBS, while both wildtype IgA1 and the γ1γ2α3 antibody bound to these bacteria. Indeed, the γ1γ2α3 construct bound even better (Table I ). These two predicted loops will be referred to as the LLG and PLAF loops.
Molecular modelling (37) suggests that these two loops occupy positions in IgA analogous to interdomain loops in IgG that are essential for binding of staphylococcal protein A (35) . The
IgA proteins mutated in the two loops have Arg substitutions, since conversion to this bulky side chain in a critical residue was thought likely to be sufficient to ablate binding. However, several lines of evidence indicate that no gross conformational changes have been introduced into the IgA mutants (7).
Effect of mutations in the predicted LLG loop of the C 2 domain
Two mutants with single point mutations in the LLG loop, the L257R and G259R mutants,
were assessed by ELISA for binding to the four streptococcal IgA-binding molecules ( Figure   4A ). The G259R mutant had apparent affinities similar to those of wildtype IgA1. In contrast, the L257R mutant displayed slightly decreased binding to the Sir22-derived peptide, and more markedly decreased binding to intact Sir22 and to β protein, but was not affected in its ability to bind the Arp4 protein. Together, these data suggest that residues in the Cα2 Figure 5B) . Thus, the binding of A442R to whole S. pyogenes bacteria was similar to that observed with wildtype IgA1. In contrast, P440R and F443R displayed markedly reduced binding, whilst no binding was observed for P440A, i.e. the effect on binding was even more dramatic for P440A than for P440R. Together, these results suggest that the PLAF loop in Cα3, and residues Pro440 and Phe443 in particular, are critical for binding of Sir22, its peptide derivative, and Arp4. As The data reported above revealed that the PLAF and LLG loops at the IgA-Fc interdomain region, which are critical for CD89 binding (6, 7) also appear to be important for binding to the bacterial IgA-BPs. Therefore we investigated the capacity of the bacterial proteins to inhibit the ability of IgA to bind to and activate CD89.
Using a rosetting assay, we found that Sir22 and the Sir22-derived peptide inhibited binding of IgA1 to human CD89, the former producing half maximal inhibition at concentrations of ~1 x 10 -8 M and the latter at ∼1 x 10 -7 M ( Figure 6A ). This effect appears to be specific since a control peptide (M5-N) did not display inhibitory ability at concentrations up to 5 x 10 -6 M. Similarly we found that Arp4 was capable of inhibiting the IgA1-CD89 interaction, with half maximal inhibition at ~1.6 x 10 -8 M ( Figure 6B ). This inhibition required the presence of an intact IgA-binding region in Arp4, since two non-IgAbinding Arp4-derivatives with short deletions in the IgA-binding region, Arp4∆450 and Arp4∆451, did not cause any inhibition. The β protein also appeared able to inhibit IgA binding to CD89, but much greater concentrations were required with half maximal inhibition only being reached at ~2 x 10 -6 M ( Figure 6C ). However, the protein G control did not influence rosette formation at equivalent concentrations. Together, these data indicate that all four of the IgA-binding bacterial molecules studied here are able to block the binding of IgAFc to CD89.
As an additional, physiologically relevant test for function, we assessed the ability of the bacterial IgA-BPs to inhibit the IgA-mediated triggering of a respiratory burst in neutrophils, characterised by NADPH oxidase activation and degranulation which can be assessed in a chemiluminescence assay. The oxidative burst is a biological response of major importance in host defence, and an ability to inhibit it would clearly be advantageous to a pathogen. Although we were unable to perform such assays with Sir22, the Sir-22 derived peptide, or β protein due to unexpected generalised effects on neutrophil bursts, we did observe that Arp4 was capable of inhibiting the IgA-triggered oxidative burst at concentrations greater than 5 x 10 -8 M (Figure 7) . This inhibition appears to be due to the ability of Arp4 to bind IgA since the two non-IgA-binding Arp4 deletion mutants Arp4∆450 exerts its function by some other mechanism (41, 42) .
The finding that unrelated IgA-BPs, expressed by S. pyogenes or GBS, bind to similar sites in IgA-Fc is reminiscent of the situation described for the two unrelated bacterial IgGbinding molecules, staphylococcal protein A and streptococcal protein G, both of which bind to the Fc domain interface in IgG (13, 35, 36, 43) . Taken together, these data imply that convergent evolution has favoured the appearance of bacterial proteins that bind to the CH2/CH3 interdomain region in IgA or IgG. Interestingly, accessibility and sequence comparison analyses, and a recent study exploiting random peptides, indicate that the interdomain region of IgG-Fc has intrinsic properties that favour binding to other proteins (44, 45) . This conclusion is supported by evidence that the Fcγ receptor of HSV-1 binds at the Cγ2/Cγ3 domain interface (46, 47) Fc is adapted from ref. 37 
